Use este identificador para citar ou linkar para este item: http://higia.imip.org.br/handle/123456789/781
Registro completo de metadados
Campo DCValorIdioma
dc.contributor.authorPinheiro, Franciele Cabral-
dc.contributor.authorLigabue-Braun, Rodrigo-
dc.contributor.authorSiqueira, Ana Cecília Menezes de-
dc.contributor.authorMatuella, Camila-
dc.contributor.authorSouza, Carolina Fischinger Moura de-
dc.contributor.authorMonteiro, Fabíola Paoli-
dc.contributor.authorKok, Fernando-
dc.contributor.authorSchwartz, Ida Vanessa Doederlein-
dc.contributor.authorSperb-Ludwig, Fernanda-
dc.date.accessioned2022-06-29T14:58:09Z-
dc.date.available2022-06-29T14:58:09Z-
dc.date.issued2021-
dc.identifier.urihttp://higia.imip.org.br/handle/123456789/781-
dc.description.abstractBackground: There is a lack of information on the role of chronic use of hydroxychloroquine during the SARS-CoV-2 outbreak. Our aim was to compare the occurrence of COVID-19 between rheumatic disease patients on hydroxychloroquine with individuals from the same household not taking the drug during the first 8 weeks of community viral transmission in Brazil. Methods: This baseline cross-sectional analysis is part of a 24-week observational multi-center study involving 22 Brazilian academic outpatient centers. All information regarding COVID-19 symptoms, epidemiological, clinical, and demographic data were recorded on a specific web-based platform using telephone calls from physicians and medical students. COVID-19 was defined according to the Brazilian Ministry of Health (BMH) criteria. Mann–Whitney, Chi-square and Exact Fisher tests were used for statistical analysis and two binary Final Logistic Regression Model by Wald test were developed using a backward-stepwise method for the presence of COVID-19. Results: From March 29th to May 17st, 2020, a total of 10,443 participants were enrolled, including 5166 (53.9%) rheumatic disease patients, of whom 82.5% had systemic erythematosus lupus, 7.8% rheumatoid arthritis, 3.7% Sjögren’s syndrome and 0.8% systemic sclerosis. In total, 1822 (19.1%) participants reported flu symptoms within the 30 days prior to enrollment, of which 3.1% fulfilled the BMH criteria, but with no significant difference between rheumatic disease patients (4.03%) and controls (3.25%). After adjustments for multiple confounders, the main risk factor significantly associated with a COVID-19 diagnosis was lung disease (OR 1.63; 95% CI 1.03–2.58); and for rheumatic disease patients were diagnosis of systemic sclerosis (OR 2.8; 95% CI 1.19–6.63) and glucocorticoids above 10 mg/ day (OR 2.05; 95% CI 1.31–3.19). In addition, a recent influenza vaccination had a protective effect (OR 0.674; 95% CI 0.46–0.98). Conclusion: Patients with rheumatic disease on hydroxychloroquine presented a similar occurrence of COVID-19 to household cohabitants, suggesting a lack of any protective role against SARS-CoV-2 infection.pt_BR
dc.language.isoenpt_BR
dc.subjectDeficiência de frutose-1,6-difosfatasept_BR
dc.subjectErros inatos do metabolismo da frutosept_BR
dc.subjectHipoglicemiapt_BR
dc.titleThe fructose-1,6-bisphosphatase deficiency and the p.(Lys204ArgfsTer72) variantpt_BR
dc.higia.programArtigos científicos colaboradores IMIPpt_BR
dc.higia.tipoArtigo Científicopt_BR
dc.higia.pages6 p.pt_BR
Aparece nas coleções:Artigos

Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
Siqueira ACM -2021.pdf232.11 kBAdobe PDFVisualizar/Abrir


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.